The Parkinsonís Progression Markers Initiative (PPMI) is a landmark clinical study to better understand the progression of Parkinsonís disease (PD). The goal of PPMI is to identify and assess biomarkers, objective measures of Parkinsonís disease in people who have PD, people who do not have PD and groups of people who may be at risk to develop PD.
PPMI is currently recruiting a new group of participants who may be at risk for PD to understand progression of biomarkers even before PD symptoms occur. †Early detection is crucial to understanding the causes of PD and developing better treatments for Parkinsonís disease. Friends and family of people with Parkinsonís can play a unique role in this research. People over 60 who do not have Parkinsonís are needed for this study, which is being conducted at 22 PD centers across the United States and in Europe.
Who is eligible to enroll in PPMI?
People over 60 who have not been diagnosed with Parkinsonís disease are eligible. Once a volunteer provides consent to participate, evaluations and assessments will be conducted to determine eligibility.†
What are the key risk factors that PPMI will investigate?
While most people with a reduced sense of smell will not develop Parkinsonís disease, loss or reduction of the ability to smell is common in people with PD. Get involved by taking the smell survey†or call (877) 525-PPMI.Take Smell Survey
To date, about 10 percent of Parkinsonís disease cases have been linked to a genetic cause, the most common of which is a mutation in the LRRK2 gene.
Studies have shown that people with RBD are at increased risk of developing neurological conditions including PD. PPMI is seeking people with RBD who do not have Parkinsonís disease and are over 60.†